FDA lifts clinical hold on Adolor’s Entereg for OBD but GSK unsure
Adolor Corp’s delight that US regulators have lifted its clinical hold on expanding development of its recently-approved bowel drug Entereg has been tempered by the news that partner GlaxoSmithKline is thinking of terminating a part of the firms’ alliance
Luxembourg top, UK ninth in European heart care study
The UK has ranked ninth in the Euro Consumer Heart Index, a survey of how consumer-friendly cardiovascular care systems are in 29 European countries
SkyePharma soars as third Flutiform trial hits endpoints
SkyePharma’s share price has climbed almost 8% after the UK drug delivery firm announced that yet another late-stage study of its flagship asthma combination drug Flutiform has proved successful
|
 |
Alabama tells pharma firms to settle or face trial in Medicaid fraud cases
Having won damages from GSK and Novartis earlier this week, the State of Alabama’s bid to get compensation from the other 69 drugmakers (a case against AstraZeneca has already gone to trial) it sued as part of a Medicaid drug pricing fraud case is gathering pace
Wyeth and Progenics get EU approval for OIC drug Relistor
Wyeth and partner Progenics Pharmaceuticals have got the backing of European regulators to sell Relistor, a treatment for opiod-induced constipation
France's Cellectis gets cash boost from Regeneron settlement
Regeneron Pharmaceuticals is to fork out almost $12.5 million to settle a licence agreement dispute with French biotechnology firm Cellectis
|